α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease

Parkinson's disease (PD) is the most common form of movement disorder and affects approximately 4% of the population aged over 80 years old. Currently, PD cannot be prevented or cured, and no single diagnostic biomarkers are available. Notably, recent studies suggest that two familial PD-linked...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2010-10, Vol.11 (11), p.4257-4266
Main Authors: Waragai, Masaaki, Sekiyama, Kazunari, Sekigawa, Akio, Takamatsu, Yoshiki, Fujita, Masayo, Hashimoto, Makoto
Format: Article
Language:English
Subjects:
alpha-Synuclein - blood
alpha-Synuclein - cerebrospinal fluid
biomarker
Biomarkers - blood
Biomarkers - cerebrospinal fluid
cerebrospinal fluid
DJ-1
Humans
Intracellular Signaling Peptides and Proteins - blood
Intracellular Signaling Peptides and Proteins - cerebrospinal fluid
Oncogene Proteins - blood
Oncogene Proteins - cerebrospinal fluid
Parkinson Disease - blood
Parkinson Disease - cerebrospinal fluid
Parkinson’s disease
Protein Deglycase DJ-1
Review
α-synuclein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson's disease (PD) is the most common form of movement disorder and affects approximately 4% of the population aged over 80 years old. Currently, PD cannot be prevented or cured, and no single diagnostic biomarkers are available. Notably, recent studies suggest that two familial PD-linked molecules, α-synuclein and DJ-1, are present in cerebrospinal fluid (CSF) and that their levels may be altered during the progression of PD. In this regard, sensitive and accurate methods for evaluation of α-synuclein and DJ-1 levels in the CSF and blood have been developed, and the results suggest that the levels of both molecules are significantly decreased in the CSF in patients with PD compared with age-matched controls. Furthermore, specific detection and quantification of neurotoxic oligometric forms of α-synuclein in the blood using enzyme-linked immunosorbent assays might be expected as potential peripheral biomarkers for PD, although further validation is required. Currently, neither α-synuclein nor DJ-1 is satisfactory as a single biomarker for PD, but combinatory evaluation of these biological fluid molecules with other biomarkers and imaging techniques may provide reliable information for diagnosis of PD.
ISSN:1422-0067
1422-0067
DOI:10.3390/ijms11114257